U.S.S.N. 10/567,021 Applicants: Lange et al.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1-7. (Canceled)
- 8. (Withdrawn, Currently Amended) A method of isolating a population of human mesenchymal stem cells comprising performing density gradient centrifugation on human bone marrow; and isolating human mesenchymal stem cells from a fraction having a density of 1.050-1.070 g/ml wherein the human mesenchymal stem cells make up at least 70% of the fraction.
- (Canceled)
- (Withdrawn, Currently Amended) The method according to claim [[9]]8, wherein said isotonic solution is Percoll® and said density is 1.068 g/ml.
- 11. (Currently Amended) A <u>population of human</u> mesenchymal stem cells obtained according to a method comprising performing density gradient centrifugation on <u>human</u> bone marrow; and isolating human mesenchymal stem cells from a fraction having a density of 1.050-1.070 g/ml_x wherein the human mesenchymal stem cells make up at least 70% of the fraction.
- 12. (Canceled)
- (Currently Amended) The mesenchymal stem cell of claim [[12]]11 wherein said isotonic-solution is Percoll@-and said density is 1.068 g/ml.
- (Currently Amended) A pharmaceutical preparation comprising a population of human mesenchymal stem cells obtained according to a method comprising

U.S.S.N. 10/567,021 Applicants: Lange et al.

performing density gradient centrifugation on bone marrow; and isolating human mesenchymal stem cells from a fraction having a density of 1.050-1.070 g/ml, wherein the human mesenchymal stem cells make up at least 70% of the fraction.

- 15. (Canceled)
- (Currently Amended) The pharmaceutical preparation of claim [[15]]14 wherein said isotonic solution is Percoll® and said density is 1.068 g/ml.
- 17. (Previously Presented) The pharmaceutical preparation of claim 14 further comprising a pharmaceutically acceptable excipient and/or carrier.
- 18. (Canceled)
- 19. (Previously Presented) The pharmaceutical preparation of claim 16 further comprising a pharmaceutically acceptable excipient and/or carrier.
- 20. (Canceled)